Clinical Oncology - 2017;4(02)

Clinical Oncology

MAY 10, 2017

[Foreword]

A szerkesztők

HUN 2017;4(02)

Clinical Oncology

MAY 10, 2017

[News from the World]

HUN 2017;4(02)

Clinical Oncology

MAY 10, 2017

[Geriatric oncology]

TELEKES András

[Geriatric oncology has an increasing role since in several types of cancer the median age at diagnosis is above 60 years of age. The treatment of elderly patients are frequently set back by prejudice, stereotypes and lack of information. All these lead to the fact that even in well-developed countries elderly cancer patients often do not receive the necessary treatments. This is even more true in poor-countries, where the fi nancial defi cit accumulated in health care is often attempted to be... tovább »

HUN 2017;4(02)

Clinical Oncology

MAY 10, 2017

[Adjuvant treatment of breast cancer]

PAJKOS Gábor

[Choice of optimal adjuvant treatment has been based on present debates, doubts and commit offence against processing or existing evidences. Clinical research has been resulted changes and renewal of practice decisions continuously. 3rd Breast Cancer Consensus Conference held on Kecskemét last year corresponded by Hungarian experts of the fi eld has given up to date and well-defi ned guideline. Present paper try to give a summary of adjuvant treatment courses for early breast cancer in... tovább »

HUN 2017;4(02)

Clinical Oncology

MAY 10, 2017

[Combination of radiotherapy and immunotherapy]

HIDEGHÉTY Katalin, BRUNNER Szilvia, SZABÓ Zoltán Imre, SZABÓ Emília Rita, POLANEK Róbert, TŐKÉS Tünde

[Increasing experimental and clinical evidences demonstrated the synergic effect between the rapidly implemented immunotherapy and advanced forms of focal radiotherapy, not only on the elimination of the irradiated lesion, but also on the enhancement the immune-mediated systemic anti-tumoral activity. It is essential for gaining the most benefi t from the combination of the two modalities to select the appropriate patients, to defi ne the irradiation parameters, such as radiation quality (ie.... tovább »

HUN 2017;4(02)

Clinical Oncology

MAY 10, 2017

[Why don’t immune checkpoint inhibitors work in colorectal cancer?]

SHI Yuequan, ZOU Zifang, KERR David

[In recent years, immune checkpoint inhibitors have been shown to be effective in treating manifold types of cancer but less robust in colorectal cancer (CRC). While, the subgroup of CRC with microsatellite instability (MSI; also termed as mismatch repair defi cient) showed a moderate response to Pembrolizumab in a single arm phase II clinical trial, microsatellite stable (MSS) cancers were unresponsive. Possible mechanisms that affect immune response in colorectal cancer will be reviewed in... tovább »

HUN 2017;4(02)

Clinical Oncology

MAY 10, 2017

[Signaling pathways in cancer stem cells (Notch, Hedgehog, Wnt)]

KOPPER László, NAGY Noémi, SEBESTYÉN Anna

[OThe key regulators in the embryonic life, and later in the differentiation of tissues and organs are the evolutionary reserved signalling pathways, as Notch, Hedgehog and Wnt. Mutations of these pathways have been identifi ed in many tumor types, increasing the risk to the appearance of cancer stem cells (CSC), with very similar geno- and phenotype as normal stem cells have. Such CSCs with stemness functions can be developed not only from normal stem cells, but also from progenitor and... tovább »

HUN 2017;4(02)

Clinical Oncology

MAY 10, 2017

[Pneumonitis - severe adverse effect of therapy]

VÁRNAI Zsuzsanna

[The interstitial lung diseases (ILD) are a heterogeneous group of disorders that are classifi ed together because of similar clinical, radiographic or pathologic manifestation. The diffuse interstitial lung diseases are divided into those that are associated with known causes and that are idiopathic. The treatment choices and prognosis vary among the different causes and types of ILD, so the early and correct diagnosis is important. In oncology ILD could be a rather severe adverse effect of... tovább »

HUN 2017;4(02)

Clinical Oncology

MAY 10, 2017

[Paleo-oncology - messages from the past]

MOLNÁR Erika, MARCSIK Antónia, PÁLFI György, ZÁDORI Péter, BUCZKÓ Krisztina, TAKÁCS Vellainé Krisztina, HAJDU Tamás

[Nowadays, cancer is one of the greatest challenges facing mankind. However, there is still no consensus among researchers regarding the antiquity of cancer. Written sources and paleo-oncological studies may help to answer this question. The aim of this study is to present data on the history of cancer based on historical sources, literature data and own research fi ndings. Early historical sources indicate that cancer was already known in antiquity. Paleopathological studies of animal and... tovább »

HUN 2017;4(02)